HIV treatment has been transformed so completely over four decades that newly diagnosed patients in 2026 have a near-normal life expectancy with appropriate ART — a fact that changes both the patient population considering trial participation and the research questions worth asking. The current trial agenda has bifurcated into two largely distinct projects. One: can we free patients from daily pills entirely, replacing them with monthly or twice-yearly injections? The PURPOSE 1 lenacapavir PrEP trial answered that question in prevention with 100% efficacy. The other, harder question: can we cure HIV by eliminating the latent viral reservoir that persists even in perfectly suppressed patients? The answer to that one is still being worked out, and the work is getting more interesting.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
In 2026, HIV research has bifurcated: long-acting regimens are now approved standard options (CAB+RPV monthly/bimonthly; lenacapavir twice-yearly), while cure research moves into serious Phase 2 territory with broadly neutralizing antibody (bNAb) combinations in analytical treatment interruption trials. Lenacapavir PURPOSE 1 showed 100% PrEP efficacy in cisgender women and adolescent girls in Africa — zero infections in the lenacapavir group. PURPOSE 2 showed 96% efficacy in MSM and transgender individuals. mRNA HIV vaccines using germline-targeting have cleared a critical early milestone and are advancing to Phase 2. HIV-associated aging and comorbidities (cardiovascular disease, neurocognitive decline) represent a growing clinical trial agenda for the long-term survivor population.
ClinicalMetric Analysis
- PURPOSE 1's 100% efficacy figure requires careful framing. The trial was conducted in a high-incidence population where daily oral PrEP consistently underperforms its clinical potential due to adherence challenges. The correct comparison isn't lenacapavir vs. perfect oral PrEP — it's lenacapavir vs. oral PrEP as actually used by real people under real-world constraints. In that framing, a twice-yearly injection is genuinely transformative. The remaining barrier is pricing and manufacturing access in high-incidence, low-resource settings — which is a policy problem, not a science problem.
- Analytical treatment interruption (ATI) carries real risk that informed consent documents must convey clearly. Viral rebound during ATI trials isn't a side effect — it's the designed endpoint. During rebound, CD4 counts can decline, and there's a window of potential infectiousness if a participant has a partner who doesn't know their status. These are cure research trials, not treatment optimization studies, and participant counseling requirements are correspondingly higher than standard trial disclosure.
- REPRIEVE's statin result implies the entire cardiovascular risk framework needs recalibration for people with HIV. Pitavastatin reduced MACE by 35% in a population that didn't meet standard statin criteria — meaning standard guidelines were underestimating CV risk in people with HIV. The clinical implication: if you're a clinician treating long-term HIV patients, Pooled Cohort Equations likely underestimate their 10-year risk, and the threshold for statin initiation should be lower than in the general population.
Long-Acting Injectable ART: Where the Field Stands
Cabotegravir + rilpivirine (CAB+RPV, Cabenuva) was approved by the FDA in January 2021 as the first complete long-acting injectable HIV regimen — two injections monthly or every 2 months instead of daily oral pills. The ATLAS and FLAIR Phase 3 trials confirmed non-inferiority to daily oral regimens in virologically suppressed adults. The appeal is obvious: adherence to a monthly injection schedule is fundamentally different from remembering a daily pill, and eliminating daily visible medication addresses privacy concerns that remain real barriers to treatment for many patients.
The limitations are worth understanding clearly. CAB+RPV requires prior viral suppression on oral ART. Rilpivirine resistance mutations (K101E, K101P, E138A/G/K/Q/R, V179L, Y188L, H221Y, F227C, M230I/L) and certain HLA-B*57:01-related hypersensitivity patterns disqualify patients. The every-2-months option requires adherence to injection timing windows — missing a window significantly extends the period of subtherapeutic drug levels, particularly for the rilpivirine component with its longer washout period. 2026 trials are working on expanding eligibility criteria, evaluating CAB+RPV in pregnant women and adolescents, and generating real-world adherence data outside controlled trial conditions.
Lenacapavir: The Twice-Yearly Injection That Changed Prevention
Lenacapavir (Sunlenca, Gilead) is a first-in-class capsid inhibitor — it disrupts the HIV capsid at multiple stages of the viral replication cycle simultaneously, giving it an unusually high genetic barrier to resistance. Its half-life after subcutaneous injection is approximately 25 weeks, enabling dosing just twice per year. It was approved in 2022 for treatment-experienced adults with multidrug-resistant HIV, but the story that matters most in 2026 is its performance as PrEP.
PURPOSE 1 enrolled cisgender women and adolescent girls in Uganda and South Africa — a population with high HIV incidence and documented adherence challenges with daily oral PrEP. The result was 100% efficacy: zero HIV infections in the lenacapavir group across the trial period, compared with background infection rates in the study populations. Zero. PURPOSE 2, conducted in MSM and transgender individuals in multiple countries, showed 96% efficacy. These are extraordinary prevention outcomes by any standard, and they suggest that the barrier to effective HIV prevention can largely be reduced to a twice-yearly healthcare encounter rather than daily pill discipline. The policy challenge — pricing, manufacturing scale, access in high-incidence low-resource settings — is now the primary obstacle, not the science.
Broadly Neutralizing Antibodies: The Cure Research Frontier
The most ambitious HIV research in 2026 targets a functional cure — long-term viral suppression in the absence of ART. The obstacle is the latent reservoir: resting memory CD4+ T cells that harbor integrated HIV provirus in a transcriptionally silent state, invisible to the immune system and unaffected by antiretroviral drugs. Broadly neutralizing antibodies (bNAbs) are antibodies that recognize conserved epitopes on the HIV envelope protein gp120 and gp41, neutralizing a wide range of HIV strains with different envelope sequences.
Early-generation bNAbs showed modest efficacy in preventing infection in the AMP trials. Next-generation bNAbs with extended half-lives — VRC07-523LS, 3BNC117-LS, 10-1074 — are in combination trials targeting viral rebound after analytical treatment interruption (ATI). The rationale for combinations: HIV evolves rapidly during ATI, and any single bNAb can be escaped by a single amino acid change in the envelope. Combinations covering different epitopes substantially raise the genetic barrier to escape. Current ATI trials are asking whether bNAb combinations, with or without latency-reversing agents (LRAs) that force latent virus to express viral proteins and become visible to the immune system, can maintain viral suppression long enough for immune clearance to occur.
The "post-treatment controllers" — people who maintain viral suppression for years after stopping ART — are being studied intensively to identify what immune factors enable this rare outcome. Understanding them is the map to functional cure research.
mRNA HIV Vaccines: A Genuinely New Design Strategy
The HIV vaccine challenge has frustrated researchers for decades. HIV mutates rapidly within hosts, has evolved multiple immune evasion mechanisms, and establishes a latent reservoir before any immune response can clear it. Conventional vaccine approaches that work well for influenza or SARS-CoV-2 don't translate. The germline-targeting approach attempts something different: activating rare B cell precursors — immunoglobulin gene configurations that, if matured correctly, can evolve into broadly neutralizing antibody producers. These precursors exist in roughly 0.001% of naive B cells; the challenge is selectively stimulating them and then guiding their affinity maturation through sequential boosts.
Moderna and IAVI advanced mRNA-1644, encoding an eOD-GT8 60mer immunogen designed to engage VRC01-class precursor B cells. Phase 1 results published in 2023 showed the vaccine successfully elicited the target precursor B cell response in 97% of recipients — a milestone that had not been achieved with any prior HIV vaccine approach. The technology is working at the priming step. Phase 2 trials are now testing whether sequential boosting with specifically designed follow-on immunogens can mature these responses into functional broadly neutralizing antibodies. The data here is still preliminary, but the mechanistic success in Phase 1 was a genuine breakthrough in vaccine science, with implications beyond HIV.
HIV and Aging: The Long-Term Survivor Agenda
With effective ART, people with HIV now have life expectancy approaching that of HIV-negative individuals — but they age differently. Rates of cardiovascular disease, neurocognitive decline, kidney disease, bone loss, and certain non-AIDS malignancies are elevated relative to demographically matched HIV-negative populations, likely due to chronic immune activation and residual inflammation even during virological suppression. The REPRIEVE trial delivered a landmark result: pitavastatin reduced major adverse cardiovascular events by 35% in people with HIV aged 40–75 with low-to-moderate CV risk who didn't otherwise meet statin criteria by standard guidelines. This established that people with HIV warrant more aggressive cardiovascular risk management than standard algorithms suggest.
HIV-associated neurocognitive disorders (HAND), which span from mild impairment to frank HIV-associated dementia, affect a significant proportion of long-term survivors even on suppressive ART. The neuroinflammation driving HAND likely involves both direct CNS viral effects and indirect effects of systemic immune activation signaling to the brain. 2026 trials are evaluating anti-inflammatory and neuroprotective approaches in this population.
Key Trial Data Points
- Lenacapavir PURPOSE 1: 100% PrEP efficacy in cisgender women and adolescent girls in Africa — zero infections vs. background incidence in the study population. PURPOSE 2: 96% efficacy in MSM and transgender individuals.
- CAB+RPV (Cabenuva): monthly or bimonthly injections confirmed non-inferior to daily oral ART in ATLAS and FLAIR Phase 3 trials — now standard of care for eligible suppressed adults.
- mRNA-1644 germline-targeting HIV vaccine: 97% of recipients developed the target VRC01-class precursor B cell response in Phase 1 — a first-ever milestone in HIV vaccine design.
- REPRIEVE trial: pitavastatin reduced MACE by 35% in people with HIV with low-to-moderate baseline CV risk, establishing a higher cardiovascular risk threshold for statin initiation in this population.
- Next-generation bNAb combinations (VRC07-523LS, 3BNC117-LS, 10-1074) are in Phase 2 ATI trials — the first serious test of whether antibody combinations can maintain viral suppression post-ART interruption.